Michael J. Brown - Feb 1, 2023 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Director
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 05:50 PM
Previous filing
Jan 3, 2023
Next filing
Feb 24, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +13.9K $0.00 13.9K Feb 1, 2023 Common Stock 13.9K $3.16 Direct F1
transaction MNPR Restricted Stock Units Award $0 +10.1K $0.00 10.1K Feb 1, 2023 Common Stock 10.1K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.
F2 RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.